A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

NCT06624644 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

135

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma (Skin Cancer)
Melanoma Stage IIIB-IV
Cutaneous Melanoma
Unresectable Melanoma

Interventions

BIOLOGICAL: LNS8801
BIOLOGICAL: Pembrolizumab
DRUG: Chemotherapy (dacarbazine or temozolomide)
BIOLOGICAL: Immunotherapy (Pembrolizumab)
BIOLOGICAL: Immunotherapy (nivolumab and relatlimab)
BIOLOGICAL: Immunotherapy (ipilimumab and nivolumab)

Sponsor

Linnaeus Therapeutics, Inc.